Lorlatinib is a targeted drug of several generations

Lorlatinib (Lorlatinib) is a reversible and potent third-generation tyrosine kinase inhibitor that is highly selective. Lorlatinibwas developed to target drug resistanceALK mutants, including the most common third-generation targeted drug in the treatment of lung cancer, G1202R. Lorlatinib is a third-generation targeted drug. Its development targets are not limited to EGFR mutations, but also include ALK (tyrosine kinase) mutations and ROS1 fusion genes. It aims to more comprehensively solve the problem of drug resistance because they can interfere with multiple signaling pathways in tumor cells, thus providing a more powerful inhibitory effect. One of the characteristics of lorlatinib is its high selectivity for multiple targets, which enables it to achieve significant clinical efficacy in patients with ALK-positive non-small cell lung cancer (NSCLC).